Neuroblastoma 1

Common Name(s)

Neuroblastoma 1

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Neuroblastoma 1" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Neuroblastoma 1" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Neuroblastoma 1" returned 208 free, full-text research articles on human participants. First 3 results:

In vivo expansion and activation of γδ T cells as immunotherapy for refractory neuroblastoma: A phase 1 study.
 

Author(s): Joseph G Pressey, Julia Adams, Lualhati Harkins, David Kelly, Zhiying You, Lawrence S Lamb

Journal: Medicine (Baltimore). 2016 Sep;95(39):e4909.

 

CD3+ γδ+ T cells comprise 2% to 5% of circulating T cells with Vγ9Vδ2+ cells the dominant circulating subtype. Vγ9Vδ2+ cells recognize non-peptide phosphoantigens and stress-associated NKG2D ligands expressed on malignant cells. Strategies that incorporate the tumoricidal properties ...

Last Updated: 30 Sep 2016

Go To URL
Expression pattern of ISL-1, TTF-1 and PAX5 in olfactory neuroblastoma.
 

Author(s): P Czapiewski, A Gorczyński, J Haybaeck, K Okoń, J Reszeć, W Skrzypczak, J Dzierżanowski, M Kunc, J Karczewska, W Biernat

Journal: Pol J Pathol. 2016 Jun;67(2):130-5.

 

Olfactory neuroblastoma (ONB) is a rare neoplasm of the sinonasal area with neuroendocrine differentiation. ISL-1, TTF-1 and PAX5 are transcription factors that are frequently upregulated in tumors showing neuroendocrine differentiation. The aim of our study was to evaluate these ...

Last Updated: 21 Aug 2016

Go To URL
Role of Nrf2, HO-1 and GSH in Neuroblastoma Cell Resistance to Bortezomib.
 

Author(s): A L Furfaro, S Piras, C Domenicotti, D Fenoglio, A De Luigi, M Salmona, L Moretta, U M Marinari, M A Pronzato, N Traverso, M Nitti

Journal:

 

The activation of Nrf2 has been demonstrated to play a crucial role in cancer cell resistance to different anticancer therapies. The inhibition of proteasome activity has been proposed as a chemosensitizing therapy but the activation of Nrf2 could reduce its efficacy. Using the highly ...

Last Updated: 30 Mar 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Neuroblastoma 1" returned 0 free, full-text review articles on human participants.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

A Cancer Research UK Trial of Anti-GD2 T-cells (1RG-CART)
 

Status: Recruiting

Condition Summary: Relapsed or Refractory Neuroblastoma

 

Last Updated: 17 Mar 2017

Go to URL

Last Updated: 21 Mar 2017

Go to URL

Last Updated: 14 Mar 2017

Go to URL